COVID-19: breaking down a global health crisis
Abstract Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first
century, with over one-hundred million infections and over two million deaths to date. It is a …
century, with over one-hundred million infections and over two million deaths to date. It is a …
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …
worldwide, critically impacting public health systems. A number of already approved and …
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Substantial COVID-19 research investment has been allocated to randomized clinical trials
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
CTR Vegivinti, KW Evanson, H Lyons, I Akosman… - BMC Infectious …, 2022 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …
threat to public health worldwide. The purpose of this study was to review current evidence …
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis
Z Kashour, M Riaz, MA Garbati… - Journal of …, 2021 - academic.oup.com
Objectives Clinical studies of chloroquine (CQ) and hydroxychloroquine (HCQ) in COVID-19
disease reported conflicting results. We sought to systematically evaluate the effect of CQ …
disease reported conflicting results. We sought to systematically evaluate the effect of CQ …
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
D Huang, H Yu, T Wang, H Yang… - Journal of medical …, 2021 - Wiley Online Library
We conducted this systemic review and meta‐analysis in an attempt to evaluate the efficacy
and safety of umifenovir in coronavirus disease 2019 (COVID‐19). We searched PubMed …
and safety of umifenovir in coronavirus disease 2019 (COVID‐19). We searched PubMed …
Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping
Objectives To assess the reporting and methodological quality of COVID-19 systematic
reviews, and to analyze trends and gaps in the quality, clinical topics, author countries, and …
reviews, and to analyze trends and gaps in the quality, clinical topics, author countries, and …
An update on antiviral therapy against SARS-CoV-2: how far have we come?
O Indari, S Jakhmola, E Manivannan… - Frontiers in …, 2021 - frontiersin.org
COVID-19 pandemic has spread worldwide at an exponential rate affecting millions of
people instantaneously. Currently, various drugs are under investigation to treat an …
people instantaneously. Currently, various drugs are under investigation to treat an …
Favipiravir in therapy of viral infections
R Łagocka, V Dziedziejko, P Kłos, A Pawlik - Journal of clinical medicine, 2021 - mdpi.com
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent
RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved …
RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved …
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …